Kang Jihoon, Kim Nayoung, Park Tae Hwan, Bang Oh Young, Lee Ji Sung, Lee Juneyoung, Han Moon-Ku, Park Seong-Ho, Gorelick Philip B, Bae Hee-Joon
Department of Neurology, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Korea.
Department of Neurology, Cerebrovascular center, Seoul National University Bundang Hospital, Seoul National University, Seongnam, Korea.
BMC Neurol. 2015 Jul 30;15:122. doi: 10.1186/s12883-015-0367-4.
We aimed to determine whether early statin use following recanalization therapy improves the functional outcome of ischemic stroke.
Using a prospective stroke registry database, we identified a consecutive 337 patients within 6 h of onset who had symptomatic stenosis or occlusion of major cerebral arteries and received recanalization therapy. Based on commencement of statin therapy, patients were categorized into administration on the first (D1, 13.4%), second (D2, 20.8%) and third day or later (D ≥ 3, 15.4%) after recanalization therapy, and no use (NU, 50.4%). The primary efficacy outcome was a 3-month modified Rankin Scale score of 0-1, and the secondary outcomes were neurologic improvement, neurologic deterioration and symptomatic hemorrhagic transformation during hospitalization.
Earlier use of statin was associated with a better primary outcome in a dose-response relationship (P for trend = 0.01) independent of premorbid statin use, stroke history, atrial fibrillation, stroke subtype, calendar year, and methods of recanalization therapy. The odds of a better primary outcome increased in D1 compared to NU (adjusted odds ratio, 2.96; 95% confidence interval, 1.19-7.37). Earlier statin use was significantly associated with less neurologic deterioration and symptomatic hemorrhagic transformation in bivariate analyses but not in multivariable analyses. Interaction analysis revealed that the effect of early statin use was not altered by stroke subtype and recanalization modality (P for interaction = 0.97 and 0.26, respectively).
Early statin use after recanalization therapy in ischemic stroke may improve the likelihood of a better functional outcome without increasing the risk of intracranial hemorrhage.
我们旨在确定再通治疗后早期使用他汀类药物是否能改善缺血性卒中的功能结局。
利用前瞻性卒中登记数据库,我们纳入了连续337例发病6小时内有症状性大脑主要动脉狭窄或闭塞并接受再通治疗的患者。根据他汀类药物治疗开始时间,患者被分为再通治疗后第1天(D1,13.4%)、第2天(D2,20.8%)和第3天及以后(D≥3,15.4%)使用,以及未使用(NU,50.4%)。主要疗效结局为3个月改良Rankin量表评分为0 - 1分,次要结局为住院期间神经功能改善、神经功能恶化和症状性出血转化。
早期使用他汀类药物与更好的主要结局呈剂量反应关系(趋势P = 0.01),且独立于病前他汀类药物使用、卒中病史、心房颤动、卒中亚型、日历年和再通治疗方法。与未使用相比,D1组获得更好主要结局的几率增加(调整优势比,2.96;95%置信区间,1.19 - 7.37)。在双变量分析中,早期使用他汀类药物与较少的神经功能恶化和症状性出血转化显著相关,但在多变量分析中并非如此。交互分析显示,早期使用他汀类药物的效果不受卒中亚型和再通方式的影响(交互作用P分别为0.97和0.26)。
缺血性卒中再通治疗后早期使用他汀类药物可能提高获得更好功能结局的可能性,而不增加颅内出血风险。